"Thiazolidinediones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).
| Descriptor ID |
D045162
|
| MeSH Number(s) |
D02.886.675.933 D03.383.129.708.933
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazolidinediones".
Below are MeSH descriptors whose meaning is more specific than "Thiazolidinediones".
This graph shows the total number of publications written about "Thiazolidinediones" by people in this website by year, and whether "Thiazolidinediones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 3 | 1 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 0 | 1 |
| 2020 | 4 | 0 | 4 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiazolidinediones" by people in Profiles.
-
Tilekar K, Hess JD, Upadhyay N, Bianco AL, Schweipert M, Laghezza A, Loiodice F, Meyer-Almes FJ, Aguilera RJ, Lavecchia A, C S R. Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPAR? and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. J Med Chem. 2021 05 27; 64(10):6949-6971.
-
Tilekar K, Upadhyay N, Schweipert M, Hess JD, Macias LH, Mrowka P, Meyer-Almes FJ, Aguilera RJ, Iancu CV, Choe JY, Ramaa CS. Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells. Eur J Pharm Sci. 2020 Nov 01; 154:105512.
-
Tilekar K, Upadhyay N, Hess JD, Macias LH, Mrowka P, Aguilera RJ, Meyer-Almes FJ, Iancu CV, Choe JY, Ramaa CS. Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential. Eur J Med Chem. 2020 Sep 15; 202:112603.
-
Davidson MB. The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease. Diabetes Res Clin Pract. 2020 07; 165:108223.
-
Upadhyay N, Tilekar K, J?nsch N, Schweipert M, Hess JD, Henze Macias L, Mrowka P, Aguilera RJ, Choe JY, Meyer-Almes FJ, Ramaa CS. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Bioorg Chem. 2020 07; 100:103934.
-
Davidson MB, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018 Jan; 135:102-110.
-
Bajpeyi S, Pasarica M, Conley KE, Newcomer BR, Jubrias SA, Gamboa C, Murray K, Sereda O, Sparks LM, Smith SR. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function. Metabolism. 2017 Apr; 69:24-32.
-
Boulin M, Diaby V, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. PLoS One. 2016; 11(9):e0162951.
-
El-Zaher AA, Elkady EF, Elwy HM, Saleh MA. Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine). J AOAC Int. 2016 Jul; 99(4):957-963.
-
Davidson MB. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications. 2016 08; 30(6):981-5.